Navigation Links
Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
Date:9/30/2013

INDIANAPOLIS, Sept. 30, 2013 /PRNewswire/ --

WHAT:   Eli Lilly and Company (NYSE: LLY) will host a meeting for the investment community, including major long-term investors, sell-side analysts, financial media and ratings agency representatives.

WHEN:   The meeting will take place Thursday, Oct. 3, 2013.  The meeting will start at 8:30 a.m. (EDT) and last until approximately 12:30 p.m. (EDT).

WHO:     Company leaders will provide an in-depth update of its financial results, its pipeline progress, and its work to sustain a flow of innovative medicines over the long-term. There will be presentations by John C. Lechleiter, Ph.D., chairman, president, and chief operation officer; Derica Rice, chief financial officer; and Jan M. Lundberg, Ph.D., executive vice president of science and technology and president of Lilly Research Laboratories. Lilly's five business presidents also will highlight the significant opportunities in each of their areas. There will Q&A opportunities throughout the meeting.

WHERE:  Lilly's investment community meeting will take place at the company's global research and corporate headquarters in Indianapolis, IN.  

HOW:     A live webcast of the Lilly investment community meeting, along with presentation slides, will be available through a link on Lilly's website at www.lilly.com. The webcast will be available for replay over the next 12 months.

Media interested in attending in-person should contact Edward Sagebiel at (317) 985-6303 or Scott MacGregor at (317) 440-4699. Investors interested in attending should contact Lilly's investor relations department.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information ─ for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. F-LLY     

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
2. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
3. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
4. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
5. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
6. Dr. Marschall S. Runge Elected to Lilly Board of Directors
7. Lilly Reports Second-Quarter 2013 Results
8. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
9. Lilly Disappointed in Draft Medicare Coverage Decision for Beta-Amyloid Imaging Agents
10. The Zacks Analyst Blog Highlights: Walgreens, Express Scripts Holding, Haemonetics, ResMed and Eli Lilly
11. Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Wegener Polyangiitis ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline Review, ... Polyangiitis,s therapeutic pipeline. This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... SILVER SPRING, Md. , Feb. 4, 2016 ... Robert Califf , the FDA,s Deputy Commissioner for Medical Products ... far-reaching action plan to reassess the agency,s approach to opioid ... the epidemic, while still providing patients in pain access to ... The FDA will: , Re-examine the risk-benefit ...
Breaking Medicine Technology:
(Date:2/5/2016)... NY & Salt Lake City, UT (PRWEB) , ... February 05, ... ... Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author ... the New Really Cool Humans Amateur TV Network. , Each week, on his weekly ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to once again host, Swirl, A Wine Tasting Event at the La Gorce ...
Breaking Medicine News(10 mins):